Zobrazeno 1 - 10
of 131
pro vyhledávání: '"Jang-Hee Hong"'
Publikováno v:
Epidemiology and Health, Vol 45 (2023)
OBJECTIVES The purpose of this study was to investigate the association between body mass index (BMI) and self-rated health (SRH) in older adults aged over 65 years while examining the influence of self-perceived body image (SBI) and sex. METHODS Raw
Externí odkaz:
https://doaj.org/article/594c0d7da563480c998efcb57df22c5b
Autor:
Kyung‐Sang Yu, In‐Jin Jang, Hyeong‐Seok Lim, Jang Hee Hong, Min‐Gul Kim, Min Kyu Park, Doo‐Yeoun Cho, Min Soo Park, Jae Yong Chung, Jong‐Lyul Ghim, SeungHwan Lee, Seok Kyu Yoon, In Sun Kwon, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Jung Bin Cha, Daniel E. Furst, Edward Keystone, Jonathan Kay
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1280-1291 (2021)
Abstract This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimum
Externí odkaz:
https://doaj.org/article/7d507bd001904a1aa34884f6d604a326
Publikováno v:
Journal of the Korean Medical Association / Taehan Uisa Hyophoe Chi; Apr2024, Vol. 67 Issue 4, p256-264, 9p
Autor:
Jae Hoon Kim, Jung Sunwoo, Ji Hye Song, Yu-Bin Seo, Won Tae Jung, Kyu-Yeol Nam, YeSeul Kim, Hye Jung Lee, JungHa Moon, Jin-Gyu Jung, Jang Hee Hong
Publikováno v:
Pharmaceuticals, Vol 15, Iss 8, p 962 (2022)
The interaction between statins and omega-3 fatty acids remains controversial. The aim of this phase 1 trial was to evaluate the pharmacokinetics of drug-drug interaction between atorvastatin and omega-3 fatty acids. Treatments were once-daily oral a
Externí odkaz:
https://doaj.org/article/f74c5ce73cf04280a4e672013fd1212e
Publikováno v:
Medicine; 10/27/2023, Vol. 102 Issue 43, p1-4, 4p
Autor:
Joo Young Na, Eunsol Yang, Jae‐Hoon Kim, In Sun Kwon, Eun‐Heui Jin, Kyung‐Sang Yu, Jinsook Kim, SeungHwan Lee, Jang Hee Hong
Publikováno v:
Clinical Pharmacology in Drug Development. 11:615-622
Hypertension and hyperlipidemia are often comorbid, requiring combination therapies of antihypertensive drugs and antihyperlipidemia drugs. Taking 1 fixed-dose combination (FDC) may increase patient compliance rather than taking each of the drugs sep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c42d59744c09dbaaf409ad217822f98
https://doi.org/10.1002/cpdd.1054
https://doi.org/10.1002/cpdd.1054
Autor:
Jin Gyu Jung, Sunghyun Kim, Bum Soo Kim, Anca Streinu-Cercel, Oana Săndulescu, Da Bee Jeon, Adrian Streinu-Cercel, Seul Gi Lee, Sang Joon Lee, Yeon Sook Kim, Yeo Jin Lee, Jin Yong Kim, Yeon Mi Lee, Min Kyung Kim, Jae-Hyeong Park, Jang Hee Hong, Jeong Eun Park, Young Rock Jang, Na Hyun Jung
Publikováno v:
Clinical Therapeutics
PURPOSE: Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be168aec276ef873b11c98eb98586b40
https://doi.org/10.1016/j.clinthera.2021.08.009
https://doi.org/10.1016/j.clinthera.2021.08.009
Autor:
Hee Sun, Byun, Eunjin, Ju, Kyeong Ah, Park, Kyung-Cheol, Sohn, Chan Seok, Jung, Jang Hee, Hong, Hyunju, Ro, Hoi Young, Lee, Khong Trong, Quan, InWha, Park, MinKyun, Na, Gang Min, Hur
Publikováno v:
Cell Biology and Toxicology.
The activation of receptor-interacting protein kinase 1 (RIPK1) by death-inducing signaling complex (DISC) formation is essential for triggering the necroptotic mode of cell death under apoptosis-deficient conditions. Thus, targeting the induction of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c16b3f604624ac66dece617087fbd4
https://doi.org/10.1007/s10565-022-09774-6
https://doi.org/10.1007/s10565-022-09774-6
Autor:
Jung Bin Cha, Jong Lyul Ghim, Yun Ju Bae, In Sun Kwon, Hyeong Seok Lim, Sung-Hyun Kim, In-Jin Jang, Daniel E. Furst, Kyung Sang Yu, Sang Joon Lee, Jae Yong Chung, Doo-Yeoun Cho, Edward C. Keystone, Min Kyu Park, Jang Hee Hong, Min Soo Park, Jonathan Kay, Min-Gul Kim, Seung-Hwan Lee, Seok Kyu Yoon
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1280-1291 (2021)
Clinical and Translational Science
Clinical and Translational Science
This study aimed to demonstrate pharmacokinetic (PK) equivalence of a single dose of the proposed adalimumab biosimilar CT‐P17 to United States‐licensed adalimumab (US‐adalimumab) and European Union‐approved adalimumab (EU‐adalimumab). This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0bf9cbad8bbb9778d884d99b5281e7
https://doaj.org/article/7d507bd001904a1aa34884f6d604a326
https://doaj.org/article/7d507bd001904a1aa34884f6d604a326
Autor:
Yu-Bin Seo, Jae Hoon Kim, Ji Hye Song, WonTae Jung, Kyu-Yeol Nam, Nyung Kim, Youn-Woong Choi, SangMin Cho, Do-Hyung Ki, Hye Jung Lee, JungHa Moon, SeungSeob Lee, JaeHee Kim, Jang Hee Hong, Jung Sunwoo, Jin-Gyu Jung
Publikováno v:
Translational & Clinical Pharmacology; Jun2023, Vol. 31 Issue 2, p95-104, 10p